CD274 and non-small cell lung carcinoma: Boeri et al. also tested the efficacy of an miRNA signature classifier (MSC) composed of 24 miRNAs in combination with PD-L1 as a prognostic marker in a cohort of 140 advanced NSCLC patients treated with ICIs, showing that the patients with intermediate- or low-risk levels in MSC and/or PD-L1 expression ≥ 50% achieved significantly higher ORR (p = 0.0024), and both PFS and OS (p < 0.0001) [34].